Vanda Pharmaceuticals To Present Data On VEC-162 At SLEEP 2007, The Annual Meeting Of The Associated Professional Sleep Societies

Main Category: Sleep / Sleep Disorders / Insomnia
Also Included In: Conferences;  Clinical Trials / Drug Trials
Article Date: 09 Jun 2007 - 0:00 PDT

email to a friend   printer friendly   opinions  

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that Dr. Tom Roth, Director of the Henry Ford Sleep Disorders and Research Center in Detroit, MI, will deliver an oral presentation on recent Phase III clinical trial results for VEC-162, Vanda's balanced melatonin (MT1/MT2) receptor agonist, at SLEEP 2007, the 21st annual meeting of the Associated Professional Sleep Societies, (APSS).

-- The Vanda presentation will take place at the Convention Center in Minneapolis, MN on June 13 from 4:00pm - 4:15pm CDT, during the 2:45 - 4:45 pm session entitled, "O31: Pharmacotherapy of Insomnia."

-- Abstract ID 0773: "Melatonin Agonist VEC-162 Improves Sleep Onset and Maintenance in a Model of Transient Insomnia" (Roth, together with G. Birznieks; C.H. Scott P. Baroldi, M.D., Ph.D.; Mihael H. Polymeropoulos, M.D., Vanda Pharmaceuticals)

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates in clinical development. Vanda's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia and bipolar disorder and has recently completed its Phase III program in schizophrenia. Vanda's second product candidate, VEC-162, is a compound for the treatment of sleep and mood disorders which is currently in Phase III for insomnia. Vanda's third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness that is in a Phase II clinical trial. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

Vanda Pharmaceuticals Inc.
http://www.vandapharma.com

• Additional
• References
• Citations